MLTX Insider Trading Activity and SEC Form 4 Filings
MLTX insider trading summary
Over the past 12 months, insiders at MoonLake Immunotherapeutics (MLTX) reported 50 sales worth $646.7M by 13 insiders and no open-market purchases on SEC Form 4. Net insider selling was $646.7M.
Latest MLTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 22, 2026 | Kristian Reich | Chief Scientific Officer | Sell | $49K (2,448 @ $20.00) |
| Jul 21, 2026 | Kristian Reich | Chief Scientific Officer | Sell | $1.0M (50,000 @ $20.02) |
| Jul 20, 2026 | Kristian Reich | Chief Scientific Officer | Sell | $878K (43,700 @ $20.09) |
| Jul 15, 2026 | Kristian Reich | Chief Scientific Officer | Sell | $322K (16,105 @ $20.01) |
| Jun 22, 2026 | Matthias Bodenstedt | Chief Financial Officer | Sell | $862K (39,120 @ $22.04) |
| Jun 18, 2026 | Matthias Bodenstedt | Chief Financial Officer | Sell | $55K (2,794 @ $19.60) |
| Jun 17, 2026 | Matthias Bodenstedt | Chief Financial Officer | Sell | $297K (15,082 @ $19.68) |
| Jun 17, 2026 | Kristian Reich | Chief Scientific Officer | Sell | $972K (50,000 @ $19.43) |
| Jun 16, 2026 | Kristian Reich | Chief Scientific Officer | Sell | $935K (50,000 @ $18.70) |
| Jun 15, 2026 | Kristian Reich | Chief Scientific Officer | Sell | $945K (50,000 @ $18.89) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.